The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,779,448 in first-year total cost, median $231,312.
Most frequent study sections
- Special Emphasis Panel[ZAI1 AZ-M (M1)]2
- Special Emphasis Panel[ZAI1 PTM-I (J1)]2
- Special Emphasis Panel[ZAI1 GEB-I (J1)]1
- Special Emphasis Panel[ZAI1 JRR-A (M3)]1
- Special Emphasis Panel[ZAI1 KP-M (J1)]1
Most frequent institutions
- RHODE ISLAND HOSPITAL2
- VANDERBILT UNIVERSITY MEDICAL CENTER2
- JOHNS HOPKINS UNIVERSITY1
- MEISSA VACCINES, INC.1
- TEMPLE UNIV OF THE COMMONWEALTH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | High vs. Standard Dose Flu Vaccine in Pediatric Solid Organ Transplant Recipients1R34AI150532-01 | HALASA, NATASHA BASSAM | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $267,620 | ZAI1 |
| 2020 | Planning the utilization of human challenge with Neisseria gonorrhoeae for vaccine testing1R34AI148072-01 | DUNCAN, JOSEPH AHOBBS, MARCIA METZGAR | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $233,250 | ZAI1 |
| 2020 | Mechanistic Assessment of Hemolytic Risk Mitigation for a Novel 8-aminoquinoline1R34AI143511-01A1 | WALKER, LARRY A | UNIVERSITY OF MISSISSIPPI, MS | $229,374 | ZAI1 |
| 2020 | A randomized, sequential dose escalation study comparing open-label T2307 to standard of care in candidemia due to Candida auris or other drug-resistant Candida species: A phase 2/3 adaptive design1R34AI150517-01 | PAPPAS, PETER GEORGE | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $222,750 | ZAI1 |
| 2020 | Biomarker Guided CNI Substitution in Kidney Transplantation1R34AI150361-01 | HEEGER, PETER SCOTTNICKERSON, PETER W | UNIVERSITY OF MANITOBA, MB | $207,050 | ZAI1 |
| 2019 | Determining the Accuracy of Cephalosporin Allergy Testing1R34AI134569-01A1 | KHAN, DAVID A | UT SOUTHWESTERN MEDICAL CENTER, TX | $292,598 | ZAI1 |
| 2019 | Treatment of SLE with sirolimus1R34AI141304-01 | PERL, ANDRAS | UPSTATE MEDICAL UNIVERSITY, NY | $243,000 | ZAI1 |
| 2019 | Volume Expansion in Children with Shiga Toxin-Producing E. coli Infection to Prevent or Mitigate Hemolytic Uremic Syndrome: Planning a Multinational Randomized Clinical Trial1R34AI136783-01A1 | FREEDMAN, STEPHEN BRADLEYSCHNADOWER, DAVIDTARR, PHILLIP I | UNIVERSITY OF CALGARY, AB | $222,699 | ZAI1 |
| 2019 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Novel Live Attenuated Respiratory Syncytial Virus Vaccine with Thermal Stable Fusion protein in Seropositive Adults and Children1R34AI143516-01 | SLOBOD, KAREN S | MEISSA VACCINES, INC., CA | $220,500 | ZAI1 |
| 2018 | Trial of Oral Doxycycline for the Treatment of Childhood Lyme Meningitis1R34AI134558-01 | GARRO, ARIS C | RHODE ISLAND HOSPITAL, RI | $261,693 | ZAI1 |
| 2018 | Private wells and enteric infections in children: A randomized intervention trial1R34AI127305-01A1 | MURPHY, HEATHER M | TEMPLE UNIV OF THE COMMONWEALTH, PA | $257,827 | ZAI1 |
| 2018 | Randomized Controlled Trial of Anti-TNF to Preserve Allograft Function in High-Risk Renal Transplant Patients Based on a B Cell Biomarker1R34AI136782-01 | ROTHSTEIN, DAVID M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $229,198 | ZAI1 |
| 2018 | NATIENS: A Phase III Randomized Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis1R34AI136815-01 | PHILLIPS, ELIZABETH | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $205,376 | ZAI1 |
| 2017 | A Pharmacokinetic and dose escalation study of low dose emetine in healthy volunteers1R34AI132003-01 | CLEMENTS, JANICE E | JOHNS HOPKINS UNIVERSITY, MD | $245,188 | ZAI1 |
| 2017 | Point-of-care C-reactive protein-based tuberculosis screening among people living with HIV: planning a comparative effectiveness trial1R34AI134589-01 | YOON, CHRISTINA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $235,938 | ZAI1 |
| 2017 | Praziquantel for children under four: A Phase II PK/PD driven dose finding trial1R34AI132000-01 | BUSTINDUY, AMAYA LOPEZFRIEDMAN, JENNIFER F | RHODE ISLAND HOSPITAL, RI | $205,387 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.